company background image
DHR logo

Danaher NYSE:DHR Voorraadrapport

Laatste prijs

US$247.76

Marktkapitalisatie

US$180.6b

7D

2.2%

1Y

25.9%

Bijgewerkt

06 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Danaher Corporation

NYSE:DHR Voorraadrapport

Marktkapitalisatie: US$180.6b

DHR Overzicht aandelen

Danaher Corporation ontwerpt, produceert en verkoopt wereldwijd professionele, medische, industriële en commerciële producten en diensten.

Over het bedrijf

Beloningen

De winst zal naar verwachting met 14.49% per jaar groeien

Risicoanalyse

DHR onze risicocontroles hebben doorstaan.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Innovative Bioprocessing Boosts Revenue Amid Diagnostics Growth And Global Expansion

Key Takeaways Continued momentum in bioproces Analysts are assu The analysts have a consensus price target of $289.75 for Danaher based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $315.0, and the most bearish reporting a price target of just $255.0. In order for you to agree with the analyst's consensus, you'd need to believe that by 2027, revenues will be $29.3 billion, earnings will come to $6.3 billion, and it would be trading on a PE ratio of 40.2x, assuming you use a discount rate of 6.4%.
View narrative
US$289.75
FV
14.5% undervalued intrinsic discount
7.28%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Updated narrative

Danaher Corporation Concurrenten

Thermo Fisher Scientific

NYSE:TMO

US$214.5b

Agilent Technologies

NYSE:A

US$40.3b

IQVIA Holdings

NYSE:IQV

US$38.6b

Mettler-Toledo International

NYSE:MTD

US$29.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Danaher
Historische aandelenkoersen
Huidige aandelenkoersUS$247.76
52 Week HoogtepuntUS$281.70
52 Week LaagUS$192.35
Bèta0.86
11 maand verandering-7.82%
3 maanden verandering-7.77%
1 Jaar Verandering25.88%
33 jaar verandering-17.97%
5 jaar verandering80.78%
Verandering sinds IPO27,841.24%

Recent nieuws en updates

Understanding Danaher's Cautiousness

Oct 25

Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Sep 28
Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Sep 25

Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Sep 12
Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Recent updates

Understanding Danaher's Cautiousness

Oct 25

Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Sep 28
Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Sep 25

Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Sep 12
Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly

Aug 28
Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly

Danaher: Lofty Price, Bright Future

Aug 22

Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

Aug 13
Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

Danaher: Valuation Now Too High Even Compared To Own High Standards

Jul 16

What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Jun 23
What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum

Jun 20

Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Jun 05
Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Is Danaher (NYSE:DHR) A Risky Investment?

May 21
Is Danaher (NYSE:DHR) A Risky Investment?

It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

May 01
It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

Value Vs. Growth? Danaher Says Why Not Both?

Apr 25

Danaher: All In On Life Sciences, And Market Update

Mar 27

Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Mar 11
Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Feb 10
Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term

Jan 30

Is Danaher (NYSE:DHR) Using Too Much Debt?

Jan 12
Is Danaher (NYSE:DHR) Using Too Much Debt?

My Top 2024 Stock Pick: Danaher

Dec 27

Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles

Nov 26

RGA Investment Advisors - Danaher:  Purity In The Crown Jewel Of Bioprocessing

Nov 19

Why Danaher Is One Of My Favorite Long-Term Investments

Oct 26

Danaher: Short-Term Headwinds, But Long-Term Tailwinds

Oct 17

Should Danaher Investors Sell New Veralto Shares?

Oct 02

Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Sep 30
Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Danaher: A Lost Year

Aug 30

Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens

Aug 02

Danaher: A Compounding Icon At A Fair Price

Jul 25

These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Jul 13
These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Jun 28
Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump

Jun 22

At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Jun 15
At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Danaher: A Great Chance To Buy This Long-Term Compounder

May 23

With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Apr 26
With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Rendement voor aandeelhouders

DHRUS Life SciencesUS Markt
7D2.2%3.7%2.3%
1Y25.9%19.8%35.1%

Rendement versus industrie: DHR overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 19.8 % opleverde.

Rendement versus markt: DHR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 35.1 % opleverde.

Prijsvolatiliteit

Is DHR's price volatile compared to industry and market?
DHR volatility
DHR Average Weekly Movement2.8%
Life Sciences Industry Average Movement8.0%
Market Average Movement6.2%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: DHR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van DHR is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
196962,000Rainer Blairwww.danaher.com

Danaher Corporation ontwerpt, produceert en verkoopt wereldwijd professionele, medische, industriële en commerciële producten en diensten. De biotechnologie segmenten bieden bioprocess technologieën, verbruiksgoederen en diensten die de ontwikkeling en productie van therapeutica bevorderen, versnellen en integreren; cellijn en celkweek media ontwikkelingsdiensten; celkweek media, proces vloeistoffen en buffers voor productie, chromatografie harsen, filtratie technologieën, aseptisch vullen afwerking; single-use hardware en verbruiksgoederen en diensten, zoals het ontwerp en de installatie van volledige productie suites; lab filtratie, scheiding en zuivering; lab-schaal eiwitzuivering en analytische instrumenten; reagentia, membranen en diensten; en gezondheidszorg filtratie oplossingen. Het segment Life Sciences biedt massaspectrometers, flowcytometrie, genomica, labautomatisering, centrifugering, automatiseringsinstrumenten voor vloeistofbehandeling, antilichamen en reagentia, en deeltjestelling en -karakterisering; microscopen; verbruiksartikelen voor eiwitten; industriële filtratieproducten; en genomische geneesmiddelen, zoals nucleïnezuurproducten op maat, plasmide DNA, RNA en eiwitten onder de merknamen ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX en SCIEX.

Danaher Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Danaher zich tot de beurswaarde?
DHR fundamentele statistieken
MarktkapitalisatieUS$180.62b
Inkomsten(TTM)US$3.93b
Inkomsten(TTM)US$23.74b

45.5x

Koers/Winstverhouding

7.5x

P/S-verhouding

Is DHR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DHR resultatenrekening (TTM)
InkomstenUS$23.74b
Kosten van inkomstenUS$9.53b
BrutowinstUS$14.22b
Overige uitgavenUS$10.28b
InkomstenUS$3.93b

Laatst gerapporteerde inkomsten

Sep 27, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)5.45
Brutomarge59.87%
Nettowinstmarge16.57%
Schuld/Eigen Vermogen Verhouding34.2%

Hoe presteerde DHR op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.4%

Huidig dividendrendement

20%

Uitbetalingsratio